June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.See Full Update

Intellia Therapeutics announces patent for CRISPR/Cas genome editing in China

Published 06/19/2017, 08:30 AM
© Reuters.  Intellia Therapeutics announces patent for CRISPR/Cas genome editing in China
NTLA
-
  • Intellia Therapeutics (NASDAQ:NTLA) announces that China’s State Intellectual Property Office will grant a patent covering CRISPR/Cas9 single-guide gene editing methods and compositions.
  • The patent includes claims covering methods for editing DNA in non-cellular and cellular settings, composition of matter and system claims for use in any setting, including claims in producing medicines for treating disease.
  • The European Patent Office and the U.K.’s Intellectual Property Office have previously issued patents from the same underlying international patent application.
  • Now read: Intellia Therapeutics (NTLA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.